The corresponding relative hazard reduction is very depending on the tumor biology than on the nodal position and extent of condition [62]. carriers may very well be better candidates for therapy with single-agent PARP inhibitors than triple-detrimental breast cancer BRCA1 Trong bài viết này, dược sĩ Lưu Văn Hoàng https://leonardop529fnv0.livebloggs.com/profile